BJ Jones has served as a member of the Board since June 2023. Mr. Jones currently serves as Chief Commercial Officer of NewAmsterdam Pharma since August 2023. He was previously the Chief Commercial Officer at Biohaven Pharmaceuticals from 2019 to 2022, which was acquired by Pfizer for $11.6B, and then was responsible for the company’s commercial integration. He has over 25 years of commercial experience in the healthcare industry and has held executive leadership roles of increasing responsibility at Takeda Pharmaceuticals, Astra Zeneca, Bristol-Myers Squibb, Boehringer-Ingelheim and NitroMed. He has significant experience in mass market product launches, including Nurtec® ODT, Abilify®, Farxiga®, Pradaxa®, BiDil® and Excedrin Migraine®. BJ has successfully built and led diverse commercial teams committed to addressing unmet patient needs across various therapeutic areas, including neuroscience (migraine, schizophrenia, bipolar, depression), cardiovascular (congestive heart failure, atrial fibrillation), diabetes (type 2 - oral and injectable), respiratory, GI, and infectious disease. Prior to joining the pharmaceutical industry, BJ served eight years in the U.S. Air Force and earned the rank of Major. He holds a Bachelor of Science degree in Human Factors Engineering from the U.S. Air Force Academy, a Master of Science degree in Industrial Engineering from Texas A&M University and an MBA from Stanford Graduate School of Business.